Loading
Life sciences · Journal article
Oncology Letters · September 23, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Therapy-related acute myeloid leukemia (t-AML) following chemotherapy in patients with small cell lung cancer (SCLC) is rare, and its clinical and genetic characteristics remain poorly elucidated.In the present study, a 53-year-old male patient with SCLC is reported.After diagnosis in June 2023, the patient received 9 cycles of etopside and cisplatin (EP) chemotherapy, 7 cycles of EP plus durvalumab and 1 cycle of etoposide plus durvalumab sequentially.Hematological abnormalities developed 23 months after the initial chemotherapy.Bone marrow aspiration revealed 28% blasts, and flow cytometry identified 36.4% abnormal myeloid blasts.Chromosomal karyotype analysis displayed 46,XY,t(11;20) (p15; q11) [7]/46,idem,add(6)(p25)[13], consistent with a diagnosis of t-AML (M2).The present case represents t-AML with a rare karyotype and extreme latency following treatment for SCLC.The present case report enriches the available genetic spectrum of t-AML associated with SCLC, suggesting the necessity for long-term hematological monitoring in patients with SCLC and provides a reference for the clinical management of dual malignancies.Therapy-related acute myeloid leukemia with a rare complex karyotype following first-line therapy for small cell lung cancer: A case report